GlassScriptPhysician profile
Stanley Bunas
NPI 1093862120
$399.87
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $14.73 · 2021: $177 · 2022: $53.72.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $180.18 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $44.67 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $37.07 | 2021-2022 | |
| Amgen INC. | $35.62 | 2020-2022 | |
| Dermira, INC. | $20.73 | 2019 | |
| Leo Pharma INC. | $18.33 | 2019 | |
| Genzyme Corporation | $17.42 | 2019 | |
| Mission Pharmacal Company | $16.83 | 2019 | |
| Pfizer INC. | $15.23 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Bunas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.